Fresh Tracks Therapeutics, Inc.
FRTX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | 0.01 | 0.01 |
| FCF Yield | -83.55% | -460.15% | -195.88% | -104.89% |
| EV / EBITDA | 1.00 | 0.21 | 0.21 | 0.50 |
| Quality | ||||
| ROIC | -64.05% | -291.09% | -161.32% | -75.84% |
| Gross Margin | 100.00% | -102.26% | -6,887.87% | -515.59% |
| Cash Conversion Ratio | 0.76 | 0.92 | 0.92 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | 170.61% | 56.19% | -62.91% | 3.95% |
| Free Cash Flow Growth | 77.59% | 46.43% | -80.41% | 44.27% |
| Safety | ||||
| Net Debt / EBITDA | 1.92 | 0.41 | 0.68 | 1.42 |
| Interest Coverage | -1,272.00 | -2,392.67 | -583.25 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -27.86 | -225.85 | 0.00 |
| Cash Conversion Cycle | 2.05 | -1.45 | 90.57 | -18.48 |